ERT

Intertek launches cGMP cell based assay services

Wednesday, April 4, 2012 10:08 AM

Intertek, a quality and safety solutions provider, has launched cGMP compliant cell based assay services for biologic therapeutics in its European Centre of Excellence for Biopharmaceuticals at Manchester, U.K.

More... »


Certara acquires Simcyp, adding preclinical research capability

Thursday, March 1, 2012 11:00 AM

Certara, a provider of drug discovery and development software and scientific consulting services, will acquire U.K-based Simcyp, a research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations.

More... »


ERT launches new corporate web site

Wednesday, February 15, 2012 03:52 PM

ERT, a global technology-driven provider of health outcomes services and customizable medical devices, has launched a new corporate web site.

More... »

FDA approves Kalydeco to treat rare form of cystic fibrosis

Friday, February 3, 2012 01:46 PM

The FDA has approved Kalydeco (ivacaftor), manufactured by Vertex Pharmaceuticals, for the treatment of a rare form of cystic fibrosis in patients ages six and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

More... »

Covance enters R&D collaboration

Thursday, January 19, 2012 08:30 AM

Covance, Inserm Transfert, a subsidiary of Inserm, and seed investment company Inserm Transfert Initiative have signed a four-year R&D collaboration.

More... »

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011 10:13 AM

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

More... »

Gilead Sciences acquires Pharmasset, looks to duplicate its HIV success in hepatitis C

Monday, November 28, 2011 08:02 AM

Consolidation among drug sponsors continues. 

More... »

CertiVox wins 2011 Bully Award

Tuesday, October 25, 2011 01:43 PM

CertiVox has received the Yearling category of the 2011 Bully Award, an honor presented by White Bull Summits to Europe’s leading technology, media and telecommunications companies.

More... »

Cytonet’s SELICA III trial expands to Canada

Wednesday, October 19, 2011 10:58 AM

Canadian health authority, Health Canada, recently granted Cytonet approval to extend the SELICA III trial, which has been open in the United States since 2010, into Canada.

More... »

Cubist Pharmaceuticals names senior VP

Tuesday, October 18, 2011 10:06 AM

Cubist Pharmaceuticals has named Jennifer Jackson, Ph.D., senior vice president of regulatory affairs. Jackson will oversee all facets of Cubist’s regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities. Jackson will report to Steve Gilman, Ph.D., Cubist’s executive vice president of research and development and chief scientific officer.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs